The initial phase of the MRFF Advisory Board’s consultation on the Strategy and Priorities closed on 6 June 2016. Research Australia drew on the extensive consultation process we undertook with our broad membership and alliance partners to respond to the consultation. We provided a submission in response to the Strategy and seven specific proposals in relation to Priorities for the MRFF. Lodged as eight separate submissions, they have been collated in a single document.
A new report from the health and medical sector says the Medical Research Future Fund (MRFF) needs to prioritise closing gaps between health research, health practice and the health economy.
Translating Research for a sustainable future comprehensively brings together the positions of 160 of Australia’s leading health and medical research organisations, companies and personnel.
The review, contributed to by prominent researchers, universities, and businesses in the field, outlines the sector’s view on priorities for the MRFF over the next two and five years.
Decades’ worth of highly-specialised experience is being added to the leadership of Research Australia, with the appointment of a new CEO and four new Board members.
Research Australia is an alliance of 160 members and supporters advocating for health and medical research in Australia.
A clinical trial investigating reducing risk of neonatal infections related to pre-labour ruptured membranes, has been awarded the inaugural Trial of the Year Award 2016 by the Australian Clinical Trials Alliance (ACTA).
Professor Johnathan Morris, chief investigator, this morning accepted the award on behalf of the trial investigators at the Clinical Trials 2016 Breakfast and Award Ceremony this morning from Health Minister Sussan Ley.
The MRFF provides a unique opportunity to transform Australian health and medical research and innovation.
The Health Minister has appointed an Advisory Board of eminent Australians to develop a five-year Strategy for the MRFF and the funding priorities for the first two years.
The Australian Medical Research Advisory Board supporting the Medical Research Future Fund (MRFF) has announced the commencement of a two stage consultation process on the five-year Strategy and two-year Priorities. The first stage is a public call for submissions.
A consultation Paper and more information in relation to making a submission are available on the Department of Health website. Submissions close on 6 June 2016. This will be followed by a second stage of targeted consultations to be held in July.
Nadia Levin is CEO of Research Australia, the peak group representing 160 members advocating for health and medical research in Australia. In response to requests for comment, she said:
“In 1965, Intel co-founder Gordon Moore correctly predicted exponential growth in computing technology, with computer power to double in capacity, and halve in price, every two years.
“Common computers since that time have gone from the size of houses to rooms to watches and beyond, and their capabilities today are at levels considered sci-fi even at the turn of this century.
Research Australia, which represents 160 health and medical research organisations, has described last night’s budget as mixed bag – with some wins, some losses and some more detail required.
“The Federal Government is making all of the right noises when it comes to innovation, health and research, and it is pleasing that they remain on the agenda,” said CEO Nadia Levin.
“The budget would be described by my members as a combination of ‘treatments, placebos and nocebos’, and the challenge for government is to back it up with funding.”
The following are some of the key announcements in the 2016-17 Budget which affect health and medical research. Information has been drawn from the budget papers, including portfolio and agency statements. The Budget papers are available here.
HEALTH PORTFOLIO
Medical Research Future Fund
The Budget has confirmed the Government’s continued commitment to the MRFF. However, it is now expected to meet the $20 billion target in 2020-21, a year later than first projected in the Budget in 2014 (Note 1). 2019-20 was confirmed as the target date for full capitalisation of the MRFF as recently as December last year, in the NISA Fact Sheet on the Biomedical Translation Fund (Note 2).
Research Australia
Health & Medical Research Awards
2015 Peter Wills Medal
The Peter Wills Medal was created in 2011 to mark research Australia’s 10th anniversary. It recognises an Australian who has made an outstanding contribution to building Australia’s international reputation in the area of health & medical research, and for harnessing government, research, industry and philanthropic collaborations to promote better health
Sharon Lewin is the inaugural director of the Peter Doherty Institute for Infection and Immunity, a joint venture between the University of Melbourne and Royal Melbourne Hospital; Professor of Medicine, The University of Melbourne; consultant infectious diseases physician, Alfred Hospital, Melbourne, Australia; and an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellow. She is an infectious diseases physician and basic scientist.
Sharon completed her medical training (MB., BS (Hons) 1986) and her PhD (1996) in Microbiology at Monash University, Melbourne Australia. She was trained in clinical infectious diseases in Melbourne (FRACP 1996) and did her post-doctoral fellowship with Professor David Ho at the Aaron Diamond Research Centre at the Rockefeller University, New York (1997-1999). David Ho was named Time Man of the Year in 1996 for his major contribution to discovering successful antiviral therapy for HIV. She was Director, Department of Infectious Diseases, Alfred Hospital and Monash University (2003-2014) and co-head of the Centre for Biomedical Research at the Burnet Institute (2011-2014), Melbourne, Australia.
She leads a large multi-disciplinary research team that focuses on understanding why HIV persists on treatment and developing clinical trials aimed at ultimately finding a cure for HIV infection. Her other research and clinical interests include understanding how the immune system recovers following treatment of HIV and the interaction between HIV and other important co-infections including hepatitis B virus. She is widely recognized for her innovative work in understanding how HIV hides on treatment using novel laboratory models and leading several early phase clinical trials of cancer drugs that alter HIV genes. Her clinical trial program is part of a close collaboration with the Department of Infectious Diseases, Alfred Hospital and Monash University.
She has published over 200 publications and her laboratory receives funding from the NHMRC, the National Institutes for Health (NIH), the Wellcome Trust and the American Foundation for AIDS Research. She has extensive collaborations in Asia including Thailand, Malaysia, China and India as well as collaborations with investigators throughout the US and Europe. She is a co-principal investigator for the Delaney AIDS Research Enterprise to find a Cure – a $25million NIH funded program grant of over 30 investigators working on immunological interventions to develop a cure for HIV.
She was the local co-chair of the XXth International AIDS Conference (AIDS2014) which was held in Melbourne July 2015, which attracted over 14,000 participants and was the largest health conference ever held in Australia. In 2015, she became a member of the council of the NHMRC and chairs the newly established NHMRC Health Translation Advisory Committee.
In 2014 she was named Melburnian of the Year. This is an award made each year by the City of Melbourne to an inspirational role model who has made an outstanding contribution to the city in their chosen field. This was the first time the award was made to a physician or scientist.
Sharon is married to Bob Milstein, a health lawyer. They have two adult sons, Alex and Max who are mad Essendon supporters. She is a passionate Melburnian!
You must be logged in to post a comment.